openPR Logo
Press release

AGENA BIOSCIENCE ANNOUNCES EXPANDED PARTNERSHIP WITH ASSUREX HEALTH

06-20-2017 04:46 PM CET | Health & Medicine

Press release from: Agena Bioscience

/ PR Agency: akampion
-- MassArray® System Selected for Assurex Health’s GeneSight Test --

San Diego, CA, June 20, 2017– Agena Bioscience today announced that Assurex Heath, a wholly owned subsidiary of Myriad Genetics, Inc., has selected the MassARRAY® System for streamlined laboratory set-up and sample processing of Assurex Health’s GeneSight test.
The GeneSight Psychotropic test helps clinicians select appropriate medications for patients with depression and other mental health conditions by analyzing how a patient’s genetic make-up will impact the patient’s response to different psychotropic medications.
Assurex Health initially selected the MassARRAY System for its laboratory-developed test because it provides a robust, simple, highly cost-effective workflow resulting in faster time-to-result and greater capacity for the laboratory. To date, Assurex Health has run over 150,000 GeneSight tests using the MassARRAY System. Going forward under the new partnership, Assurex Health expects to significantly increase the number of GeneSight test samples run on the platform.
“Agena Bioscience is passionate about providing affordable multiplex molecular systems to laboratories worldwide to help them significantly expand access to clinically relevant genomic data. Pharmacogenomics testing is a foundational application in the sweet spot for targeted genetic analysis on our MassARRAY System. We are proud to be chosen by Assurex Health, and see the partnership as a significant accelerator into this clinical market segment,” said Pete Dansky, Chief Executive Officer at Agena Bioscience.
The MassARRAY System enables high-throughput, accurate detection of SNPs, INDELs, and copy number variations across a variety of genetic applications. The flexibility and scalability of the platform facilitate easy development of custom panels and validation across large numbers of samples.
Assurex Health Vice President, Laboratory Operations, Sandra Gunselman, Ph.D. commented, “The GeneSight test has seen tremendous adoption and growth, with hundreds of thousands of patients tested. We are committed to providing our customers with rapid turnaround time and scalability that enables us to meet the ever-growing demand for the test. With fewer touch points and less variability in workflow, our team can continue to accelerate service to psychiatrists and their patients.”
The GeneSight Psychotropic test is supported by five published clinical studies demonstrating its efficacy and cost effectiveness. For more information visit www.genesight.com.

# # #

About Agena Bioscience
Agena Bioscience develops, manufactures, and supplies genetic analysis systems and reagents, including the MassARRAY® System. The system is a highly sensitive, cost-effective, mass spectrometry-based platform for high-throughput genetic analysis, and is used globally in diverse research fields such as cancer profiling for solid tumors and liquid biopsies, inherited genetic disease testing, pharmacogenetics, agricultural genomics, and clinical research. For more information about Agena, visit www.agenabio.com.

About Assurex Health
Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc., is an informatics-based, personalized medicine company providing treatment decision support to healthcare providers for behavioral health and chronic pain conditions. Assurex helps people achieve mental wellness with advanced CPGx®, a proprietary combinatorial pharmacogenomics technology that provides individualized treatment support for neuropsychiatric conditions. Assurex Health is the only company in the category with multiple peer-reviewed, published studies that demonstrate the clinical validity and clinical utility of the GeneSight® test, including its substantial healthcare cost savings benefit. The Company has grown every quarter and has expanded internationally through a partnership with Canada’s Centre for Addiction and Mental Health (CAMH). For more on how Assurex Health is helping people gain mental wellness, visit www.AssurexHealth.com.

Media Contact:
Agena Bioscience
Mickie Henshall
4755 Eastgate Mall,
San Diego, CA 92121
USA
(858) 882-2707
mickie.henshall@agenabio.com

Myriad Genentics/Assurex Health
Ron Rogers
(804) 504-8071
rrogers@myriad.com

European Contact:
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release AGENA BIOSCIENCE ANNOUNCES EXPANDED PARTNERSHIP WITH ASSUREX HEALTH here

News-ID: 588084 • Views:

More Releases from Agena Bioscience

Agena Bioscience Launches High-Throughput, Low-Cost SARS-CoV-2 Detection Panel i …
San Diego, CA, September 28, 2020 - Agena Bioscience, a global provider of low cost and high-throughput molecular testing solutions, today announced that it has obtained CE-IVD marking for its SARS-CoV-2 Panel, an in vitro diagnostic test for the qualitative detection of the SARS-CoV-2 coronavirus that causes COVID-19. Clinical laboratories can process more than 6000 samples each day running the assay on a single MassARRAY® instrument, making it one of
Agena Bioscience and Intermountain Healthcare Announce Research Collaboration to …
12 July 2017 SAN DIEGO, CA, AND SAINT GEORGE, UTAH – Agena Bioscience and Intermountain Healthcare announced today a strategic collaboration that focuses on expanding the use of Agena’s MassARRAY® System in oncology applications. The collaboration concentrates on expansion of Agena’s technology with the goal of focused panels for liquid and tissue biopsy. The molecular tests augment laboratory services available worldwide from Intermountain Precision Genomics to advance precision medicine in
Agena Bioscience Launches CE-IVD System For Hospitals And Diagnostic Laboratorie …
-- MassARRAY® System with Chip Prep Module receives CE-IVD marking for general in vitro diagnostic use in Europe -- San Diego, CA, June 29, 2017– Agena Bioscience today announced the European launch of the MassARRAY® System with CHIP Prep Module (CPM), marketed as a CE-IVD product under the Directive 98/79/EC for in vitro diagnostic medical devices. The MassARRAY Dx product offers clinical laboratories a unique combination of reliability, sensitivity, ease

All 4 Releases


More Releases for Assurex

Drug Free Depression Treatment Market 2022: Analysis by Top Key Players - McLean …
Drug Free Depression Treatment Market Scope and Overview 2022 The study includes an examination of the current outlook, which is expected to influence the future potential of the Drug Free Depression Treatment industry. The study also examines and analyzes COVID-19's current and prospective market results, as well as a contemporary perspective on the current state of the industry. It also includes critical information such as historical growth analysis, CAGR status, price
Pharmacogenomics (PGx) Market Exact Estimates of Upcoming Trends and Growing Dem …
A detailed overview of parent market provide insight on changing Pharmacogenomics (PGx) Market dynamics in the industry and In-depth Pharmacogenomics (PGx) Market segmentation. It also offers historical, current, and projected market size regarding volume and value along with recent industry trends and developments in the Pharmacogenomics (PGx) Market. The report also provides information on the competitive landscape and strategies for key players and products along with potential and niche segments,
Sports and Fitness Genomics and Pharmacogenomics Market To Show Strong Growth & …
The ‘ Sports and Fitness Genomics and Pharmacogenomics market’ research report added by Report Ocean, is an in-depth analysis of the latest developments, market size, status, upcoming technologies, industry drivers, challenges, regulatory policies, with key company profiles and strategies of players. The research study provides market overview, Sports and Fitness Genomics and Pharmacogenomics market definition, regional market opportunity, sales and revenue by region, manufacturing cost analysis, Industrial Chain, market effect
Global Pharmacogenomics (PGx) Market 2019 Key Players: Abbott Laboratories, Affy …
Pharmacogenomics (PGx) Market: WiseGuyReports.com adds “Pharmacogenomics (PGx) Market 2019 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting 2025” reports to its database. Executive Summary Pharmacogenomics is the study of the role of the genome in drug response. Its name reflects its combining of pharmacology and genomics. Pharmacogenomics analyzes how the genetic makeup of an individual affects his/her response to drugs. In 2018, the global Pharmacogenomics (PGx) market size was xx million US$ and
Pharmacogenomics Market Experts Analysis to 2023 | Assurex Health Inc., Future S …
The Global Pharmacogenomics Market is presumed to register 5.8% CAGR during the forecast period (2017-2023) owing to the rising prevalence of several infectious and non-infectious diseases, asserts Market Research Future (MRFR). Pharmacogenomics refers to the study of inherited variations in the human genes that affect an individual’s reaction to a specific drug. Various genetic tests are performed in pharmacogenomics to determine targeted drug therapies and treatment procedures to be adopted
Pharmacogenomics Market 2023 – Major Participant | 23andMe Inc, Pathway Genomi …
The Global Pharmacogenomics Market is expected to grow at a ~CAGR of 5.8% during the forecast period. Pharmacogenomics defines how genes can affect a person’s response to drugs. Pharmacogenomics is predicted to treat a wide range of health problems including cardiovascular diseases, Alzheimer disease, cancer, HIV/AIDS, and asthma, in near future. The growing biotech industry boosts the market growth. According to the Organization for Economic Co-operation and Development in 2017, biotech